Convalescent plasma: new evidence for an old therapeutic tool?
- PMID: 26674811
- PMCID: PMC4781783
- DOI: 10.2450/2015.0131-15
Convalescent plasma: new evidence for an old therapeutic tool?
Abstract
Passive immunisation for the prevention and treatment of human infectious diseases can be traced back to the 20(th) century. The recent Ebola virus outbreak in West Africa has turned the spotlight onto the possible use of convalescent whole blood and convalescent plasma in the treatment of infectious diseases because they are the only therapeutic strategy available in some cases, given the unavailability of vaccines, drugs or other specific treatments. Convalescent blood products could be a valid option in the treatment/prophylaxis of several infectious diseases both in association with other drugs/preventive measures and as the only therapy when a specific treatment is not available. However, there are still some issues to consider in determining the advisability of implementing a large-scale convalescent plasma transfusion programme.
References
-
- Rajam G, Sampson J, Carlone GM, Ades EW. An augmented passive immune therapy to treat fulminant bacterial infections. Recent Pat Antiinfect Drug Discov. 2010;5:157–67. - PubMed
-
- Virdi V, Depicker A. Role of plant expression systems in antibody production for passive immunization. Int J Dev Biol. 2013;57:587–93. - PubMed
-
- World Health Organization. WHO Blood Regulators Network (BRN) Geneva: World Health Organization; Aug 14, 2014. Position Paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. 2014.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases